Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 0.77 |
| ▸ | ESR1 | P03372 | 13/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22413393 | 0.94 | ESR2 (0.71) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6828078 | 0.87 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6828126 | 0.84 | ESR2 (0.73) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6825403 | 0.84 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL26766938 | 0.84 | ESR2 (0.62) | ESR2ESR1 | |
| SCHEMBL6825266 | 0.83 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL22431062 | 0.83 | ESR2 (0.76) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL6824968 | 0.82 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1 | |
| SCHEMBL6828637 | 0.81 | ESR2 (1.00) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL26768203 | 0.80 | ESR2 (0.79) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | claimed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | ESR2 4060/4885ESR1 4838/4885KDM4E 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.